Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The DPC4 gene may play a role as a tumor-suppressor gene in a fraction of colorectal cancers; however, while allelic loss at 18q21 is very often seen in colorectal cancers, only a minority show DPC4 mutations, suggesting that there might be another tumor-suppressor gene in this chromosome region.
|
8898652 |
1996 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Twenty-five of 84 tumors had homozygous deletions at 18q21.1, a site that excludes DCC (a candidate suppressor gene for colorectal cancer) and includes DPC4, a gene similar in sequence to a Drosophila melanogaster gene (Mad) implicated in a transforming growth factor-beta (TGF-beta)-like signaling pathway.
|
8553070 |
1996 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
RT-PCR sequencing analysis of the HL60 Smad5 remaining allele ruled out the functional inactivation of the gene analogous to that occurring in the Smad5 homologs DPC4 and Smad2 in cases of pancreatic and colorectal cancers.
|
9264367 |
1997 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that DPC4 is rarely if ever mutated during prostatic oncogenesis, whereas inactivation of this gene may contribute to the genesis of a subset of colorectal carcinomas.
|
9285566 |
1997 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
DPC4 and MADR2/JV18-1 are recently demonstrated to be altered in pancreatic and colorectal cancers, respectively.
|
9288786 |
1997 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Even in combination with changes in SMAD-4, the observed frequency was not sufficient to account for all 18q21 deletions in colorectal cancers.
|
9820171 |
1998 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Other members of the SMAD family are excellent candidates for JPS, especially SMAD2 (which, like SMAD4, is mutated somatically in colorectal cancers), SMAD3 (which causes colorectal cancer when "knocked out" in mice), SMAD5, and SMAD1.
|
10446110 |
1999 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of DPC4/SMAD4 gene in colorectal cancers, we examined 73 tumors of clinical stages II or III from Japanese patients, for LOH at 18q21 and also for subtle mutations anywhere within the coding region of DPC4/SMAD4.
|
10479724 |
1999 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our data show selective up-regulation of receptor-activated Smad proteins in human colorectal cancers and suggest involvement of Smad4 in differentiation and apoptosis of surface epithelial cells of normal crypts.
|
10389752 |
1999 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data suggest that the carcinogenetic pathways of protruding and superficial depressed colorectal cancers are different, and that alterations of tumor suppressor gene(s) located on 18q21 other than Smad2, Smad4 and DCC might be associated with most superficial depressed colorectal cancers.
|
10665650 |
1999 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis.
|
10340381 |
1999 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic SMAD4 mutations have been detected in some colorectal carcinomas.
|
10993648 |
2000 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Smad4 plays a pivotal role in the TGF-beta signaling pathway and has been identified as a tumor suppressor, being mutated or deleted in approximately 50% of pancreatic carcinomas and 15% of colorectal cancers.
|
11553622 |
2001 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We investigated the prevalence of DPC4 loss of heterozygosity in sporadic colorectal cancer.
|
11357936 |
2001 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that somatic alteration of the DPC4 gene may play a role in tumorigenesis and liver metastasis of human colorectal cancers.
|
11172591 |
2001 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
|
11159190 |
2001 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although SMAD4 mutations have been associated with late-stage or metastatic disease, our combined molecular and cytogenetic data best fit a model in which SMAD4 mutations occur before colorectal cancers become aneuploid/polyploid, but after the MSI(+) and MSI(-) pathways diverge.
|
11481457 |
2001 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SMAD4 expression was absent in 20 of 53 (38%) unselected colorectal carcinomas, and reduced in another 15 (28%) cases.
|
12077092 |
2002 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, these results may provide a refinement at the gene level of the clinical relevance of 18q21 deletion, thereby suggesting SMAD4 as a predictive marker in colorectal cancer.
|
12237773 |
2002 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that whereas Smad4 point mutations are prevalent in pancreatic carcinoma, they are infrequent in early stages (I-III) of colorectal cancer.
|
12569386 |
2003 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, thus far few studies have analyzed the impact of numerical abnormalities of chromosomes 17 and 18, which carry the p53 and DCC plus SHAD4/DPC4 genes involved in colorectal cancer, on the clinical and biological behaviors of the disease.
|
12500293 |
2003 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Residing in this region are the Madh2 and Madh4 genes, which have both been implicated in human colorectal cancer.
|
12584607 |
2003 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Following the definition of SMAD4 deletion as a negative predictive marker for chemotherapy benefit in patients with CRC, we aimed to evaluate the clinical relevance of the deletion of other SMAD genes clustered in this region: SMAD2 and SMAD7 in 264 CRC biopsies from a previous clinical study.
|
12584741 |
2003 |